ASTRAZENECA’S EXPERIMENT Firm hopes a move to Europe’s largest BIOTECH COMMUNITY, Cambridge, will boost its anemic drug pipeline
LIBERTY TRUST & COUNTRYSIDE PROPERTIES
BUSINESS
ALEX SCOTT, C&EN LONDON
THE BICYCLE-FILLED city of Cambridge,
England, has been closely tied to biotechnology since 1953, when Francis H. C. Crick and James D. Watson discovered the structure of DNA in the University of Cambridge’s Cavendish building. Other luminaries that once studied at the university include Isaac Newton and Charles Darwin. Attracted by the university’s high caliber of academic research, today about 200 biotech companies make their own discoveries in and around Cambridge. Joining them in 2016 will be AstraZeneca. The big British drug company will pluck about 2,000 researchers from Alderley
Park, its R&D site in a remote part of northern England, and other locations, and set them down in Cambridge’s bustling biotech community. The firm hopes that embracing a new model of collaboration will enable it to reinvent itself as an innovative force. “Our people will be able to rub shoulders with some of the world’s best scientists and clinicians,” said Pascal Soriot, AstraZeneca’s chief executive officer, when he announced the move in June. Success will come from developing new therapies through collaborations with Cambridge’s world-leading institutes and the university. But the move comes at a
difficult time for AstraZeneca. With 2012 sales down 15% and a weak drug development pipeline, the firm is under pressure to ensure its relocation contributes strongly from the outset. AstraZeneca will locate on the Cambridge Biomedical Campus, the city’s largest science complex. It will spend about $530 million to build a new company headquarters and a separate R&D headquarters by 2016, taking up 11 acres of CBC’s 70-acre campus. The site will bring together the
t "O *UBMJBO XPSMEDMBTT NBOVGBDUVSFS PG"DUJWF1IBSNBDFVUJDBM*OHSFEJFOUT "1*T BOEBEWBODFEJOUFSNFEJBUFT t 1SPEVDUJPOQMBOUT'%"JOTQFDUFE t )JHI1PUFODZ$POUBJONFOUJO DPNQMJBODFXJUIUIFTUSJDUFTU JOUFSOBUJPOBMSFRVJSFNFOUT t )JHIRVBMJUZTUBOEBSETPCUBJOFE BMTPXJUIUIFVTFPG'MPX3FBDUPST
OLON’S MAJOR AREAS OF EXPERTISE: s &ERMENTATIONAND3EMI SYNTHESIS s (IGH0OTENCY$RUGS s #ONTRACT-ANUFACTURINGAND #USTOM3YNTHESIS Please contact us at:
/LON3P! 3TRADA2IVOLTANAKM 2ODANO-ILAN )4!,9 4ELEPHONE 4ELEFAX %MAILFDEGRADI OLONSPAIT www.olonspa.it
CEN.ACS.ORG
32
OCTOBER 7, 2013
As AstraZeneca integrates into Cambridge, the firm could experience a few bumps. “Tensions may well erupt, triggered either by real issues such as restrictive consultancy agreements, or failure of AstraZeneca to be open and share data with an academic partner, or ideological positions, such as the notion that the presence of commercial research dilutes fundamen-
firm’s small-molecule and biologics R&D activities, opening opportunities to exploit the promise of small- and largemolecule combinations, it says. AstraZeneca’s presence on the campus will include the company’s largest center for oncology research as well as scientists developing therapies for cardiovascular and metabolic diseases; respiratory, inflammation, and autoimmune diseases; and conditions of the central nervous system. OLD ENGLAND When
building work at CBC is completed in 2016, it will feature narrow streets and quads, as this model shows, for researchers to meet in, similar to the ones Crick and Watson once enjoyed.
CBC BOASTS a stellar cast of potential
biotech partners for AstraZeneca, such as the University of Cambridge School of Clinical Medicine, the Medical Research Council (MRC) Laboratory of Molecular Biology, the Wellcome Trust-MRC Institute of Metabolic Science, and the Cancer Research UK Cambridge Institute. And AstraZeneca already has a couple of ongoing collaborations with CBC denizens. The site also features Addenbrooke’s Hospital, a world-renowned teaching hospital. CBC is about to start building a series of facilities including a hotel and conference center that will open at the same time AstraZeneca takes up residence. CBC also has plans for a multitenancy research facility in the next few years that will accommodate more than 40 biotech firms. The site’s headcount of 7,000 is set to double during the next decade. Although the design of the campus is contemporary, it will also feature narrow streets and quads—not unlike those that Crick and Watson once enjoyed 3 miles away in the old university—to encourage researchers to meet. CEN.ACS.ORG
33
OCTOBER 7, 2013
tal research,” cautions Gregory Winter, a pioneer of therapeutic monoclonal antibodies and former director of the MRC Laboratory of Molecular Biology. But “the real issues can be dealt with by simple practical steps, such as the use by AstraZeneca of reasonable consulting agreements and a determination within AstraZeneca to have as open a culture as is consis-
BUSINESS
tent with commercial goals,” says moves by other pharma majors Winter, an influential figure who away from their own one-compaTALKING WITH THE NEIGHBORS is also the Regius Professor of ny research campuses into bioIn Cambridge, AstraZeneca will be alongside Physic at Cambridge University tech communities. One example a series of renowned research centers and the master of Trinity College. is Pfizer’s closure of its R&D site ORGANIZATION ACTIVITY The benefit to companies bein Sandwich, England, and its reCambridge University Fundamental research ing on the same site as academics location of some staff in the U.S. Medical Research Council Molecular biology is that firms can become aware of from its Groton, Conn., complex Laboratory of Molecular Biology fundamental research and its imto the Boston area. Another is Wellcome Trust-MRC Institute of Research & education Metabolic Science plications at an earlier stage than Sanofi’s exit from Bridgewater, Addenbrooke's Hospital Clinical trials & general health care they might otherwise. “Properly N.J., also in favor of Boston. Babraham Institute Biological research handled, this can translate to a Wellcome Trust Sanger Institute Genomics & genetics research commercial advantage,” Winter EVEN BEFORE AstraZeneca European Bioinformatics Basic research in computational biology says. arrives at CBC, Cambridge is Institute AstraZeneca could also eduranked by many experts as the Cancer Research UK Application of basic research on cancer Cambridge Institute cate the Cambridge community largest biotech cluster in Europe. about industry. It could even It has about 25% of the U.K.’s 979 fund some academic projects in biotech companies. Cambridge anticipation of commercial development, seeking partnerships. “The biotech comcontinues to take the lead in monoclonal Winter says. Other potential advantages munity in Cambridge without exception antibody technology, in particular, says include the ability to hire academics lookhas welcomed the news that AstraZeneca Steve Bates, CEO of the BioIndustry Assoing to move on or whose research contracts is coming to town,” says Jeanette Walker, ciation, a U.K. industry group. have expired and the sharing of expensive project director for CBC. She manages real Wider opportunities for collaborating instruments and infrastructure. estate at CBC and acts as a matchmaker to with biotech firms and academia exist in This summer’s news that AstraZeneca ensure that the right clinicians, academics, London and Oxford, each about an hour will move to Cambridge has been warmly and industry scientists connect. from Cambridge. This area, the so-called received, which is important for a company AstraZeneca’s planned relocation follows golden biotech triangle, has attracted the professionals committed to success
,OOKINGFOR CHEMISTRY
s!0)MANUFACTURINGFROMGRAMS TOHUNDREDSOFKILOGRAMS s#USTOMORGANICSYNTHESIS
expertise in challenging chemistries
s&4%SERVICESLONG TERM ANDSHORT TERM
relationships built to last
s0ROCESSDEVELOPMENT s!NALYTICALSERVICES INCLUDING.%7 8 2AY0OWDER$IFFRACTIONAND 4RIPLE1UAD-ASS3PEC
our expertise, your solution
Visit us at CPhI Worldwide 22-24 October 2013 at Messe Frankfurt Hall 5.0/Booth # 50F01
¸ 3MALLMOLECULES ")'IDEAS» W W W. S A LT I G O. C O M | P H A R M AT E A M @ S A LT I G O. C O M
-ENDENHALL /AKS 0ARKWAY s (IGH 0OINT .# s s WWWPHARMACORECOM
CEN.ACS.ORG
34
OCTOBER 7, 2013
Pharmaceutical Outsourcing: Saltigo is dedicated to custom synthesis and manufacturing – confidentially, reliably, efficiently, and globally. Based on decades of experience, a broad and growing technology base and our own intellectual property, we provide tailored supply solutions. Our skilled employees know how to handle challenging chemistries employing explosive, corrosive or toxic reagents and highly exothermic reactions. Saltigo provides quality and safety in every respect, from the kilogram to the multi hundred ton scale. At our integrated, FDA-approved site in Leverkusen, Germany, we employ cGMP standards according to your needs. Our professionals are committed to your success!
enthusiasm of London’s charismatic mayor, Boris Johnson. He is seeking to develop Medical City, a cluster of biotech firms near research centers such as University College Hospital and the Wellcome Trust. “It’s about finding and using what levers we can to attract that talent in promoting the golden triangle as the largest conglomeration of science on the planet,” says Kit Malthouse, chairman of the mayor’s promotional body, London & Partners. Although the golden biotech triangle may offer certain opportunities, AstraZeneca’s focus seems squarely on Cambridge. The firm has been leveraging its biologics subsidiary, MedImmune, which has 500 staffers in Granta Park, a science park several miles south of Cambridge, to foster relationships with prospective partners in the town. Scientists on Babraham Research Campus, the Babraham Institute’s facility at CBC, already have good relations with MedImmune staff and are looking forward to mixing with researchers from AstraZeneca, says Babraham CEO Derek Jones, who lunched with Soriot before AstraZeneca announced it was coming to town. Babraham Institute is an independent charitable organization involved in biomedical research. AstraZeneca already has a number of projects with its prospective neighbors under way. One of them, with Cancer Research UK and Cambridge’s oncology department, is evaluating a new technology that can monitor the activity of a tumor without the need for multiple biopsies.
pies, including personalized medicines. “Clinicians and scientists at CBC are very excited about this type of collaboration,” he adds. “There is a huge difference between AstraZeneca being on site and them not being here. You have got industry, academia, and patients all on one site. It is unique.” Sixty years ago when Crick and Watson
made their famous discovery, they dashed across the street from the Cavendish labs to the Eagle pub and announced, “We have discovered the secret of life!” AstraZeneca’s Soriot is no doubt hoping that before too long his scientists, with their collaborative partners alongside them, will be rushing to a campus pub to announce discoveries of their own. ◾
Experience makes a world of difference. Ash Stevens has been providing the Life Sciences industry with contract pharmaceutical manufacturing services for more than 50 years. s s s s s s
Process research, development, and scale-up Early-stage to commercial API manufacturing Highly potent drug substance development and cGMP manufacturing Analytical development and validation Comprehensive regulatory support Preparation of documentation for submission (IND, NDA, DMF, CTD)
To see how our experience can help your drug development program succeed, call or visit us online today.
734-282-3370
IN ANOTHER collaboration—with
Babraham, Cancer Research UK, and Cambridge’s oncology department—AstraZeneca is evaluating new approaches to treating pancreatic cancer, a disease that has a poor outlook and few available treatments. The collaboration will focus on identifying the best drugs to combine with AstraZeneca’s investigational cancer treatment selumetinib. The focus of AstraZeneca’s initial partnerships is on “delivering new medicines for cancer and developing the idea of personalized health care—helping understand the underlying mechanisms of disease so the right patient receives the right medicine or the medicine is tailored to an individual patient and an individual patient’s tumor,” says Robert Winter, managing director of Eastern Academic Health Science Network, an organization dedicated to converting research into new theraCEN.ACS.ORG
35
OCTOBER 7, 2013
ashstevens.com
